These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 21641684

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
    Such Díaz A, Barrueco N, Esteban Alba C, Escobar Rodríguez I.
    Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
    [No Abstract] [Full Text] [Related]

  • 3. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec 03; 159(11):I-14. PubMed ID: 24297207
    [No Abstract] [Full Text] [Related]

  • 4.  Pegylated interferon, but not conventional interferon therapy induced severe skin lesions.
    Li Z, Ji F, Zheng Y, An J, Peng Z.
    Ann Hepatol; 2012 Dec 03; 11(4):570-1. PubMed ID: 22700642
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study [KULDS] Group.
    J Gastroenterol Hepatol; 2012 Jul 03; 27(7):1233-40. PubMed ID: 22098185
    [Abstract] [Full Text] [Related]

  • 6. [Necrotic lesion in a patient with hepatitis C virus liver disease under treatment with pegylated interferon].
    Rosel L, Blanco JR, Metota L, Oteo JA.
    Enferm Infecc Microbiol Clin; 2004 Oct 03; 22(8):497-8. PubMed ID: 15482692
    [No Abstract] [Full Text] [Related]

  • 7. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May 03; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 8. [Information for patients. Treatment of acute hepatitis C].
    Otón Nieto E.
    Rev Esp Enferm Dig; 2011 Oct 03; 103(10):549. PubMed ID: 22054273
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y, Kanto H, Itoh M.
    J Dermatol; 2007 Aug 03; 34(8):577-82. PubMed ID: 17683392
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
    Vinagre I, Rigla M, Torras X, Enríquez J, Corcoy R.
    Endocrinol Nutr; 2010 Oct 03; 57(8):393-5. PubMed ID: 20462813
    [No Abstract] [Full Text] [Related]

  • 13. Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection.
    Bachmeyer C, Moguelet P, Gombeaud T, Sbidian E, Aractingi S.
    Arch Dermatol; 2011 Oct 03; 147(10):1232-3. PubMed ID: 22006152
    [No Abstract] [Full Text] [Related]

  • 14. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
    Tsilika K, Tran A, Trucchi R, Pop S, Anty R, Cardot-Leccia N, Lacour JP, Ortonne JP, Passeron T.
    JAMA Dermatol; 2013 Jun 03; 149(6):675-7. PubMed ID: 23553009
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous reactions to interferon and ribavirin.
    Chamberlain AJ, Poon E.
    Intern Med J; 2004 Aug 03; 34(8):519. PubMed ID: 15317557
    [No Abstract] [Full Text] [Related]

  • 16. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC, Chien RN.
    Aliment Pharmacol Ther; 2013 Feb 03; 37(4):492. PubMed ID: 23336679
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
    Virolés Torrent S, López Nuñez C, Hombrados Verde M, Figa Francesch M, Ferri Iglesias MJ, Louvriex Freire R, Acero Fernández D.
    Gastroenterol Hepatol; 2015 Feb 03; 38(2):78-81. PubMed ID: 24948444
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
    Papastergiou V, Skorda L, Lisgos P, Karatapanis S.
    Acta Gastroenterol Belg; 2011 Dec 03; 74(4):582-4. PubMed ID: 22319972
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.